ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Alexander B Olawaiye, MD
Study ID
NCT05071937
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ZEN003694 — DRUG
    ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
  • Talazoparib — DRUG
    Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.

Study Details

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

Key Dates

Start date
Apr 21, 2023
Status verified
Jun 2025
Primary completion
Dec 31, 2031
Completion
Mar 1, 2033

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ZEN003694 + Talazoparib
    ZEN003694: 48.0 mg daily (oral) in 28-day cycles Talazoparib: 0.75 mg daily (oral) at the same time as ZEN003694

Primary Outcome Measure

Objective Response [ Time Frame: Up to 48 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Pittsburgh Medical CenterPittsburghPennsylvania15213
Kelsey Mitch, BSN
[email protected]
412-641-2357
Lucia Borasso, BSN
[email protected]
412-641-3304
Alexander B Olawaiye, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Pittsburgh Medical Center· Pittsburgh, PA

Related Studies